falsefalse

Assessing Liver Function in Patients with HCC - Episode 8

Rivoceranib plus Camrelizumab for First-Line Treatment of HCC: Data from CARES-310

, ,

Rachna Shroff, MD, MS, FASCO, shares data from the CARES-310 study showing improved progression-free and overall survival in patients with hepatocellular carcinoma treated with camrelizumab and rivoceranib compared to sorafenib, regardless of liver function.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Risk Factors of Hepatocellular Carcinoma (HCC)
    EP. 2: Importance of Assessing Liver Function in HCC
    EP. 3: Assessing Liver Function in Patients With HCC: The ALBI Score
    EP. 4: Assessing Liver Function in Patients With HCC: The Child-Pugh Score
    EP. 5: Assessing Liver Function in Patients With HCC: The MELD Score
    EP. 6: Updates in First-Line Systemic Therapy for Patients With HCC
    EP. 7: Key Outcomes Data in Patients With HCC Based on Liver Function
    Now Viewing
    EP. 8: Rivoceranib plus Camrelizumab for First-Line Treatment of HCC: Data from CARES-310
    EP. 9: The Future of Liver Function Assessments in HCC

    Related Content:

    Assessing Liver Function in Patients with HCCInsightsInsights Video Series
    Safety Insights From the CABINET Trial
    Efficacy, Tolerability, and Quality of Life with ADCs in Gynecological Malignancies
    Interpreting the Clinical Efficacy of Cabozantinib in NETs
    x